Literature DB >> 24346421

Vasopressin antagonists for patients with acute heart failure: interpreting new clinical and translational data.

A M Feldman1, E Hamad2, E J Tsai1, W Zhu3, D G Tilley4, R Alvarez2, J Y Cheung5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24346421     DOI： 10.1038/clpt.2013.240

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  4 in total

1.  The Bayh-Dole Act, a lion without claws.

Authors:  Arthur M Feldman
Journal:  Clin Transl Sci       Date:  2015-02       Impact factor: 4.689

2.  Vasopressin type 1A receptor deletion enhances cardiac contractility, β-adrenergic receptor sensitivity and acute cardiac injury-induced dysfunction.

Authors:  Melissa A Wasilewski; Laurel A Grisanti; Jianliang Song; Rhonda L Carter; Ashley A Repas; Valerie D Myers; Erhe Gao; Walter J Koch; Joseph Y Cheung; Arthur M Feldman; Douglas G Tilley
Journal:  Clin Sci (Lond)       Date:  2016-09-02       Impact factor: 6.124

Review 3.  Arginine vasopressin receptor signaling and functional outcomes in heart failure.

Authors:  Melissa A Wasilewski; Valerie D Myers; Fabio A Recchia; Arthur M Feldman; Douglas G Tilley
Journal:  Cell Signal       Date:  2015-07-30       Impact factor: 4.315

4.  β-adrenergic receptor-mediated cardiac contractility is inhibited via vasopressin type 1A-receptor-dependent signaling.

Authors:  Douglas G Tilley; Weizhong Zhu; Valerie D Myers; Larry A Barr; Erhe Gao; Xue Li; Jianliang Song; Rhonda L Carter; Catherine A Makarewich; Daohai Yu; Constantine D Troupes; Laurel A Grisanti; Ryan C Coleman; Walter J Koch; Steven R Houser; Joseph Y Cheung; Arthur M Feldman
Journal:  Circulation       Date:  2014-09-09       Impact factor: 29.690
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.